Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis

Oncologist

Volumn 18, Issue 1, 2013, Pages 8-13

  van de Water, Willemien ^a   Seynaeve, Caroline ^b   Bastiaannet, Esther ^a   Markopoulos, Christos ^c   Jones, Steve E ^d   Rea, Daniel ^e   Hasenburg, Annette ^f   Putter, Hein ^a   Hille, Elysée T M ^a   Paridaens, Robert ^g   de Craen, Anton J M ^a   Westendorp, Rudi G J ^a   van de Velde, Cornelis J H ^a   Liefers, Gerrit Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d US Oncology Research   (United States)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Elderly; Hormone receptor positive; Outcome; Recurrence

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECURRENCE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84873038287     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0315     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Cancer of the Breast. SEER Stat Fact Sheets. Available at http: //seer. cancer. gov/statfacts/html/ breast. html#incidence-mortality. Accessed September 6, 2012.
3. Diab SG, Elledge RM, Clark GM. Tumor characteristicsandclinicaloutcomeof elderlywomenwith breast cancer. J Natl Cancer Inst 2000; 92: 550-556.
4. Mirza NQ, Vlastos G, Meric F et al. Predictors of locoregional recurrence among patients with earlystage breast cancer treated with breast-conserving therapy. Ann Surg Oncol 2002; 9: 256-265.
5. Elkhuizen PH, van de Vijver MJ, Hermans J et al. Local recurrence after breast-conserving therapy for invasive breast cancer: High incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 1998; 40: 859-867.
6. van de Water W, Markopoulos C, van de Velde CJH et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 2012; 307: 590-597.
7. van de Velde CJH, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 2011; 377: 321-331.
8. van Nes JGH, Seynaeve C, Jones S et al. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg 2010; 97: 671-679.
9. International Society of Geriatric Oncology. Available at http: //www. siog. org. Accessed September 6, 2012.
10. Yancik R, Wesley MN, Ries LA et al. Effect ofage and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-892.
11. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: Anoverview of the randomised trials. Lancet 2005; 366: 2087-2106.
12. Clark RM, Whelan T, Levine M et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update. Ontario Clinical Oncology Group. J Natl Cancer Inst 1996; 88: 1659-1664.
13. Courdi A, Largillier R, Ferrero J-M et al. Early versus late local recurrences after conservative treatment of breast carcinoma: Differences in primary tumor characteristics and patient outcome. Oncology 2006; 71: 361-368.
14. Veronesi U, Marubini E, Del Vecchio M et al. Local recurrences and distant metastases after conservative breast cancer treatments: Partly independent events. J Natl Cancer Inst 1995; 87: 19-27.
15. Livi L, Paiar F, Saieva C et al. Breast cancer in the elderly: Treatment of 1500 patients. Breast J 2006; 12: 353-359.
16. Forrest AP, Stewart HJ, Everington D et al. Randomisedcontrolled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet 1996; 348: 708-713.
17. Fisher B, Bryant J, Dignam JJ et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20: 4141-4149.
18. Fyles AW, McCready DR, Manchul LA et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351: 963-970.
19. Early Breast Cancer Trialists' Collaborative Group, Darby S, McGale P et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Metaanalysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716.
20. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: Anoverview of the randomised trials. Lancet 2005; 365: 1687-1717.
21. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of therandomisedtrials. Lancet 1998; 351: 1451-1467.
22. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
23. Schaapveld M, Visser O, Louwman WJ et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: A population based study in the Netherlands. Breast Cancer Res Treat 2008; 110: 189-197.
24. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293: 1073-1081.
25. Leonard R, Ballinger R, Cameron D et al. Adjuvant chemotherapy in older women (ACTION) study: What did we learn from the pilot phase? Br J Cancer 2011; 105: 1260-1266.
26. Ring A, Reed M, Leonard R et al. The treatment of early breast cancer in women over the age of 70. Br J Cancer 2011; 105: 189-193.
27. Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13: e148-e160.
28. Fulop T, Kotb R, Fortin CF et al. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci 2010; 1197: 158-165.
29. Pawelec G, Derhovanessian E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol 2010; 75: 165-172.
30. Lichtman SM, Wildiers H, Launay-Vacher V et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43: 14-34.
31. van de Water W, Bastiaannet E, Hille ETM et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: A TEAM study analysis. The Oncologist 2012; 17: 55-63.
32. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.